# Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/camrelizumab-versus-placebo-in-combination-with-gemcitabine-and-cisplatin-as/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yunpeng Yang,Song Qu,Jingao Li,Chaosu Hu,Mingjun Xu,Weidong Li,Ting Zhou,Liangfang Shen,Hui Wu,Jinyi Lang,G. Hu,Zhanxiong Luo,Zhichao Fu,Shenhong Qu,Weineng Feng,Xiaozhong Chen,Shaojun Lin,Weimin Zhang,Xiaojiang Li,Yan Sun,Zhixiong Lin,Qin Lin,Lei Feng,Jianting Long,Jinsheng Hong,Xiaoming Huang,Lingzhi Zeng,Peiguo Wang,Xiaohui He,Ben Zhang,Qing Yang,Xiao‐Jing Zhang,Jianjun Zou,Wenfeng Fang,Li Zhang |
| Citations | 461 |
| DOI | 10.1016/s1470-2045(21)00302-8 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3177205810 |
| PMID | 34174189 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Yunpeng Yang](https://scholariq.org/researchers/yunpeng-yang/)
- [Weineng Feng](https://scholariq.org/researchers/weineng-feng/)
- [Xiao‐Jing Zhang](https://scholariq.org/researchers/xiao-jing-zhang/)
- [Wenfeng Fang](https://scholariq.org/researchers/wenfeng-fang/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

## Paper topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Head and Neck Surgical Oncology](https://scholariq.org/topics/head-and-neck-surgical-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.